New Zealand markets closed

The Hershey Company (HSY)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
187.57+0.60 (+0.32%)
At close: 04:00PM EDT
187.95 +0.38 (+0.20%)
Pre-market: 08:00AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close186.97
Open187.30
Bid0.00 x 1800
Ask188.79 x 1800
Day's range186.76 - 189.33
52-week range178.82 - 211.92
Volume756,019
Avg. volume1,349,170
Market cap37.943B
Beta (5Y monthly)0.36
PE ratio (TTM)20.79
EPS (TTM)9.02
Earnings date07 Nov 2024
Forward dividend & yield5.48 (2.92%)
Ex-dividend date16 Aug 2024
1y target est200.19
  • Simply Wall St.

    A Look Into Hershey's (NYSE:HSY) Impressive Returns On Capital

    If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...

  • Yahoo Finance Video

    Roblox, Hershey, Samsung: 3 Stocks In Focus

    Morning Brief hosts Seana Smith and Brad Smith analyze the top trending tickers on the Yahoo Finance platform: Roblox (RBLX) is in focus after Hindenburg Research alleged that the gaming platform's metrics are inflated and there are reputational risks for advertisers who use it. Hershey's (HSY) stock is under pressure following a downgrade from UBS Securities, lowering its rating from Buy to Neutral. The firm cites rising cocoa prices (CC=F) as a potential threat to gross margins and has also reduced its price target on the stock. Samsung (005930.KS) has issued a profit warning for the third quarter, citing intense competition and delivery delays as key factors. The tech giant has taken the unusual step of publicly apologizing for its underperformance. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith

  • Investing.com

    GLP-1 drug demand rising, but not all packaged food companies in the crosshairs

    Investing.com -- As signs emerge that demand for GLP-1 drugs is stronger than expected, many are fearing the worst for packaged-food companies, but Bernstein believes that some companies are likely to fare better than others as patients on these weight-loss drugs shift appetite in favor of more protein-based foods.